We report a case of loss of diabetic control in a patient given high doses of inhaled fluticasone propionate for asthma.A 67 year old man who had had asthma for 10 years was referred for respiratory assessment. He had had noninsulin dependent diabetes mellitus for 40 years and was taking glibenclamide 5 mg and metformin 1700 mg daily. Glycaemic control was monitored every six weeks in an outpatient clinic using the percentage of glycated haemoglobin (haemoglobin A 1c ) (Corning-Drew Glycomat low pressure chromatography system).1 The normal range is < 6% and the within batch coefficient of variation is 2.6% and 1.5% for concentrations of 7% and 10% respectively. During the previous year he had had only occasional trace glycosuria ( < 2 positive urinary glucose readings a week) and glycated haemoglobin concentrations (measured every 8 weeks) ranged from 7.0% to 7.3% (data not shown). His asthma treatment comprised ipratropium bromide 0.5 mg and salbutamol 5 mg by nebuliser four times daily. Computed spirometry (12 hours after his last nebuliser) showed that forced expiratory volume in 1 second was 1.48 litres (45% of predicted values) and 1.98 litres 30 minutes after bronchodilatation (Morgan plethysmograph). He had taken no other drugs and no oral corticosteroids in the previous 6 months. He did not drink alcohol or smoke. He was meticulous in taking his treatment and in recording his peak expiratory flow rate twice daily (morning and evening before treatment using a hand held mini-Wright meter) and urinary glucose measurements (Baker Diagnostics).At week 0 he started treatment with inhaled fluticasone propionate 2000 g per day by metered dose inhaler through a Volumatic spacer device (figure). During the next 30 weeks of monitoring he did not take oral corticosteroids, his diabetic treatment and strict diet and exercise regimens remained unchanged, and his weight remained stable. After starting inhaled fluticasone propionate subjective breathlessness and wheeze improved and average weekly peak expiratory flow rate increased from 410 l/min to 440 l/min, but he developed persistent glycosuria during week 3. All 28 urinary glucose measurements were positive for glucose in weeks 3 and 4 and the dose of inhaled fluticasone propionate was thus reduced in a stepwise fashion to 500 g per day in week 14.To our knowledge, deterioration in diabetes has not been documented with the use of inhaled corticosteroids. Furthermore, tolerance to the hyperglycaemic effect of systemic corticosteroids might have explained the subsequent improvement in diabetic control between weeks 15 and 24. 4 With his consent we rechallenged him (single blind fashion) by increasing his daily dose of inhaled fluticasone propionate from 500 g to 1000 g in week 25. Within a week he developed glycosuria (from week 24 to 28, 21 out of 70 urinary readings were positive for glucose). Glycosuria resolved after reducing the dose of fluticasone propionate.In this case the administration of high dose inhaled fluticasone propionate was matched by both a ris...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.